FDA Approves Daratumumab in Combo for Multiple Myeloma Ineligible for ASCT

On June 27, the  U.S. Food and Drug Administration (FDA) announced approval of daratumumab (Darzalex^®) in combination with lenalidomide and dexamethasone (Rd) for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant (ASCT).

Read FDA announcement.